Italian biotech companies Takis and
Rottapharm Biotech on Wednesday reached a deal to develop a
vaccine against the coronavirus conceived by Takis and called
COVID-eVax.
Within the framework of the accord, a statement said,
Rottapharm Biotech will place at Takis's disposal its experience
in the development of innovative drugs and financial support up
to at least the completion of phases one and two of clinical
trials.
The first three million euros have already been agreed for
ongoing programmes and human testing is expected this autumn.
ALL RIGHTS RESERVED © Copyright ANSA
